Editorial Board About Us

Nocturia

All articles from this key word are listed below.

Volume 4, Supplement 4 Supplement

Clinical Impact of Overactive Bladder

Nocturia Quality of life Overactive bladder Incontinence Epidemiology

Volume 8, Number 4 Meeting Reviews

Advances in the Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia

Meeting Review

Claus G Roehrborn

Highlights from the 21st European Association of Urology Congress, April 5–8, 2006, Paris, France [Rev Urol. 2006;8(4):216-225]

Benign prostatic hyperplasia Nocturia Lower urinary tract symptoms Alfuzosin Prostatectomy PDE-5 inhibitors TURP Dutasteride Sexual dysfunction Acute urinary retention Chronic inflammatory infiltrates PVP High-energy transurethral microwave thermotherapy

Volume 9, Number 3 Meeting Reviews

Best of the 2007 AUA Annual Meeting

Meeting Review

J Curtis Nickel Jacob Rajfer Claus G Roehrborn Michael K Brawer Dean G Assimos Danil V Makarov Ellen Shapiro Alan W Partin Michael B Chancellor

Highlights from the 2007 Annual Meeting of the American Urological Association May 19-24, 2007 Anaheim, CA [Rev Urol. 2007;9(3):133-154]

Prostate cancer Obesity Benign prostatic hyperplasia Antibiotic prophylaxis Nocturia Lower urinary tract symptoms Botulinum toxin Prostate-specific antigen Biomarkers PCA3 Testosterone Urinary tract infections Urolithiasis Laser ablation Endourology Male voiding dysfunction LHRH antagonists Antimuscarinic agents Circumcision Repeat biopsy Human glandularkallikrein Expectant management CRISP-3 MSP Microvesseldensity Endoglin Survivin Telomeres Interleukin-8 PDE-5 inhibitors Acute urinaryretention 5Alpha-reductase inhibitors Doxazosin Finasteride Transurethral microwave thermotherapy TURP Perioperative blood loss Microbialbiofilms HIV Stem cell injection

Volume 13, Number 2 Meeting Reviews

New Findings in Benign Prostatic Hyperplasia and Incontinence

Highlights From the 26th Annual Congress of the European Association of Urology, March 18-22, 2011, Vienna, Austria

Amir Kazzazi Bob Djavan Roman Herout Alexander Farr Sabina Sevcenco

[Rev Urol. 2011;13(2):112-117 doi: 10.3909/riu0526]

Benign prostatic hyperplasia Nocturia Incontinence

Volume 14, Number 3 Review Articles

Nocturia: Focus on Etiology and Consequences

Disease State Review

Jeffrey P Weiss

Nocturia is a condition characterized by the need to awaken ≥ 1 times per night to void. Although nocturia is a multifactorial condition that can coexist with other lower urinary tract symptoms, the most common causal factor is nighttime overproduction of urine. Many people with nocturia do not seek help, accepting it as a natural consequence of aging. However, nocturia is common in men and women of all ages and has a profound impact on quality of life, especially in the young, that may be associated with increased morbidity and mortality. Nocturia as a condition deserves public health attention. [Rev Urol. 2012;14(3/4):48-55 doi: 10.3909/riu0576] © 2013 MedReviews®, LLC

Nocturia Quality of life Sleep disruption Nighttime urine overproduction

Volume 18, Number 1 Review Articles

Falls in the Elderly Secondary to Urinary Symptoms

Prevention and Management Update

Yousef Soliman Richard Meyer Neil Baum

Falls and fractures have a significant impact on our patients, their families, and caregivers, and cost the health care system billions of dollars. Each year, millions of adults aged 65 and older fall. Falls can cause moderate to severe injuries, such as hip fractures and head traumas, and can increase the risk of early death. Fortunately, falls are a public health problem that is largely preventable. Because many patients with falls and subsequent fractures have urologic conditions, urologists are positioned to help with the prevention of these significant and costly injuries. This article discusses the epidemiology of falls and fractures, and the urologic comorbidities that increase their risk. [Rev Urol. 2016;18(1):28-32 doi: 10.3909/riu0686] © 2016 MedReviews®, LLC

Nocturia Overactive bladder Falls Fractures Urinary tract infections Prevention

Volume 20, Number 1 Review Articles

Nocturia: Evaluation and Current Management Strategies

Management Update

Casey G Kowalik Joshua A Cohn Sophia Delpe Melissa R Kaufman Doug F Milam Alan J Wein W Stuart Reynolds Roger R Dmochowski

Nocturia is a complex condition that not only significantly affects quality of life, but may be an indicator of systemic disease. Initial assessment includes a detailed history and physical examination and completion of a frequency volume chart to help identify underlying causes, such as sleep disorders, bladder storage disorders, and polyuria. Treatment with alpha-blockers or antimuscarinic medications may help if the underlying cause is determined to be benign prostatic hyperplasia or overactive bladder, respectively. Treatment options for nocturnal polyuria have been limited to behavioral therapy and off-label use of timed diuretics and desmopressin. Desmopressin acetate nasal spray (Noctiva™, Avadel Pharmaceuticals, Chesterfield, MO) was approved by the US Food and Drug Administration in 2017 for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least twice nightly and has shown efficacy in reducing nocturnal voids by $50% in up to 49% of patients in clinical trials. [Rev Urol. 2018;20(1):1–6 doi: 10.3909/riu0797] © 2018 MedReviews®, LLC

Benign prostatic hyperplasia Nocturia Desmopressin Nocturnal polyuria Overactive bladder

Volume 21, Number 2 Review Articles

Nocturia in Patients With Multiple Sclerosis

Management Review

Roger R Dmochowski W Stuart Reynolds Benjamin M Brucker Benoit Peyronnet Xavier Gamé Lauren B Krupp Gérard Amarenco Jean-Nicolas Cornu Lana Zhovtis Ryerson Carrie Lyn Sammarco Jonathan E Howard Robert W Charlson

The prevalence of nocturia in patients with multiple sclerosis (MS) is high, ranging from 20.9% to 48.8% in this population. Its underlying pathophysiology is complex and different from the non-neurogenic population. In the MS population, the pathophysiology may involve neurogenic lower urinary tract dysfunction (NLUTD) such as detrusor overactivity (NDO), detrusor-sphincter dyssynergia, or detrusor underactivity resulting in reduced bladder capacity. Nocturnal polyuria is also a significant contributor to the pathogenesis of nocturia in MS patients and may be the result of specific mechanisms such as nocturnal hypertension through autonomic cardiovascular dysfunction or lack of diurnal variation of antidiuretic hormone production (ADH) due to demyelinating lesions of the spinal cord. Nocturia might be particularly burdensome in MS patients by contributing to fatigue, a common and highly debilitating symptom in this population. There is likely a complex and multidirectional relationship between nocturia, other sleep disorders, and fatigue in the MS population that has yet to be explored. The assessment of nocturia in MS should rely upon a thorough history and physical examination. Urinalysis should be done to rule out urinary tract infection, a frequency-volume chart might help elucidating the underlying mechanisms, and post-void residual volume may be of interest to screen for urinary retention that could be asymptomatic in MS patients. Other tests such as urodynamics or polysomnography are indicated in selected patients. The treatment should be tailored to the underlying cause. The first steps involve behavioral interventions and treatment of cofactors. When possible, the predominant mechanism should be addressed first. In case of predominant NDO, antimuscarinics and beta-3 agonists should be offered as a first-line treatment and intradetrusor injections of botulinum toxin as a second-line treatment. In cases of incomplete bladder emptying, clean-intermittent self-catheterization is often used as part of multiple other interventions. In cases of nocturnal polyuria, desmopressin may be offered, inclusive of use of newer formulations (desmopressin acetate nasal spray, desmopressin orally disintegrated tablet) in countries where they are approved. [Rev Urol. 2019;21(2/3):63–73] © 2019 MedReviews®, LLC

Nocturia Multiple sclerosis Fatigue Desmopressin Nocturnal polyuria voiding diary